Objective: To compare the prevalence of selective reporting in ME/CFS research areas: psychosocial versus cellular.
Background
= 0·0013, p < 0·05) over 52 weeks (White et. al., 2011) . ME/CFS support 48 groups have rejected this treatment regimen due to harms from post-exertion 49 malaise after GET, and no improvements after CBT. Biomolecular findings 50 further support these claims with evidence of cellular level harms detected af-51 ter GET (Cook et. al., 2017) , and have proposed biomarkers that are unique 52 to ME/CFS (Fluge et. al., 2016) . The consensus is that ME/CFS is a com-53 plex, multi-faceted disorder that requires a multi-disciplinary approach, and that may choose to replicate this search strategy. This search strategy did not scope for treatment effects as done in systematic reviews, but on research 73 trends in selecting high impact trials for a bias appriasal. and Adaptive Pacing Therapy) to represent psychosocial trends (White et. 79 al., 2011); 2. A neural study (NS) on post-exertion malaise after GET to 80 represent cellular trends (Cook et. al., 2017) . 3. A gut study (GS) on 81 profiling gut microbial differences in ME/CFS individuals (Giloteaux et. al., 82 2017) to also represent cellular trends. In table 1, biases were categorised 83 by: "study design", "selection" and "measurement." Each potential bias was 84 rated by the author with a plus (+) or a minus sign (-) to indicate whether 85 a study presented evidence (E) or a justification (J) for resolving a potential 86 bias. The first two columns E and J rated PACE (White et. al., 2011) . The 87 next two columns E and J rated GS (Giloteaux et. al., 2017) ; followed by 88 ratings for NS (Cook et. al., 2017) . The column "Neural Study" offered an 89 example of each rating from Cook and colleagues' (2017) paper. The column 90 "Potential Biases" defined these biases in public health terms. The far right 91 column with the letters "T", "P", "D", "R": Theory (theories and models 92 used in the trial); Place (operational conduct); Recruitment (participant 93 recruitment); Data (data practices) were collated to predict the areas of 94 strengths and weaknesses (selective reporting) in each trial. Figure 2 : Summary of bias ratings. "+" sign indicates evidence or justifications present in the trial, "-" sign indicates it was not present. Areas "T", "P", "D", "R" stand for Theory, Place, Data and Recruitment to represent the potential weak areas in the trial. ME/CFS research trends: psychosocial or cellular were compared using 98 a 2x2 contingency table to determine the strength of evidence (table 1) 99 and justifications (table 2) . Columns E and J from the bias appraisal Finally, Z tests (two-tailed) were performed to assess whether the use 106 of evidence or justifications were significantly different between the two 107 research trends.
Secondary outcome 109
The OR (primary outcome) was applied to the total number of ME/CFS The Chinese University of Hong Kong) and verified for accuracy in 117 another web-based, effect-size calculator (Campbell Collaboration).
118
Evidence E+ E-NS 21 11 PACE 15 17 
Results

119
The search strategy identified 1750 published articles for psychosocial 120 ME/CFS research and 1015 for cellular ME/CFS research between the dates 121 1951 to 25 March 2017 (day the search was performed). All articles were 122 included in observing research trends: psychosocial versus cellular ( fig. 1 ).
123
Of interest were altmetric scores scoped manually in a psychosocial trial and baseline measures that were relevant to sourcing serum samples. al., 2015; Lian & Nettleton, 2015) . However, the results also suggest, cellular 226 trials are also likely to engage in selective reporting, but its therapeutic ben-227 efit is difficult to assess, since no study as of yet have proposed a therapeutic 228 agent (eg. drug) exclusively designed and marketed for treating ME/CFS 229 (Collatz et. al., 2016) . Brurberg and colleagues (2014) propose the need for 230 consistency in ME/CFS research by applying a diagnostic criteria, subject 231 to a systematic evaluation. This need to adequately define ME/CFS is a 232 recurring consensus among researchers (Jason, Boulton & Friedberg, 2010; 233 Nacul et. al., 2011; . Some propose a re-evaluation 234 of domains and criteria in existing patient reported outcome measurements 235 (PROMs) by considering subgroups to account for heterogeneity (different 236 populations) in comorbid conditions (eg. thyroid issues) and patient char-237 acteristics (eg. children) (Nacul et., al., 2011; Haywood, Staniszewska & 238 Chapman, 2012 ; Johnston et. al., 2014; Haywood, Collin & Crawley, 2014; 239 Hvidberg et. al., 2015; Murdock et. al., 2016) . Others propose the need 240 to investigate biomarkers and immune-mediated networks in developing a 241 prophylactic agent (Fuite, Vernon & Broderick, 2008; Schlauch et. al., 2016; 242 Vega et. al., 2017; Armstrong et. al., 2017) . I dedicate this to ME Awareness Week 2017. I would like to thank ME 262 groups for your passionate advocacy and for sharing your stories with me.
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